{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:30:09Z","timestamp":1791282609410,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Theoretical Biology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.jtbi.2016.03.038","type":"journal-article","created":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T01:45:48Z","timestamp":1459907148000},"page":"43-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Mathematical modeling and systems pharmacology of tuberculosis: Isoniazid as a case study"],"prefix":"10.1016","volume":"399","author":[{"given":"Laure","family":"Lalande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bourguignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Maire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtbi.2016.03.038_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1086\/605605","article-title":"Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig","volume":"200","author":"Ahmad","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jtbi.2016.03.038_bib2","first-page":"94","article-title":"Counts of viable tubercle bacilli in sputum related to smear and culture gradings","volume":"49","author":"Allen","year":"1992","journal-title":"Med. Lab. Sci."},{"key":"10.1016\/j.jtbi.2016.03.038_bib3","doi-asserted-by":"crossref","first-page":"6971","DOI":"10.1073\/pnas.94.13.6971","article-title":"Virus dynamics and drug therapy","volume":"94","author":"Bonhoeffer","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jtbi.2016.03.038_bib4","first-page":"355","article-title":"The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review","volume":"313","author":"Burman","year":"1997","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.jtbi.2016.03.038_bib5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1086\/513945","article-title":"Activity of amoxicillin\/clavulanate in patients with tuberculosis","volume":"26","author":"Chambers","year":"1998","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.jtbi.2016.03.038_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0962-8479(92)90077-W","article-title":"The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis","volume":"73","author":"Chan","year":"1992","journal-title":"Tuber. Lung"},{"key":"10.1016\/j.jtbi.2016.03.038_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.tube.2006.06.001","article-title":"Intracellular growth and drug susceptibility of Mycobacterium tuberculosis in macrophages","volume":"87","author":"Chanwong","year":"2007","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jtbi.2016.03.038_bib8","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1128\/AAC.46.8.2358-2364.2002","article-title":"Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jtbi.2016.03.038_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"Dartois","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jtbi.2016.03.038_bib10","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1128\/AAC.45.7.1972-1976.2001","article-title":"Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis","volume":"45","author":"Dietze","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jtbi.2016.03.038_bib11","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1472-9792(08)70038-6","article-title":"The early bactericidal activity of anti-tuberculosis drugs: a literature review","volume":"88","author":"Donald","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jtbi.2016.03.038_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1586\/14787210.1.1.141","article-title":"Early bactericidal activity of antituberculosis agents","volume":"1","author":"Donald","year":"2003","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.jtbi.2016.03.038_bib13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1164\/ajrccm.156.3.9609132","article-title":"The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis","volume":"156","author":"Donald","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jtbi.2016.03.038_bib14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1086\/424999","article-title":"The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid","volume":"39","author":"Donald","year":"2004","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.jtbi.2016.03.038_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tube.2003.08.003","article-title":"M. tuberculosis persistence, latency, and drug tolerance","volume":"84","author":"Gomez","year":"2004","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jtbi.2016.03.038_bib16","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1164\/rccm.200305-682OC","article-title":"The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis","volume":"168","author":"Gosling","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jtbi.2016.03.038_bib17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jtbi.2011.05.013","article-title":"Mathematical modeling of pulmonary tuberculosis therapy: insights from a prototype model with rifampin","volume":"282","author":"Goutelle","year":"2011","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.jtbi.2016.03.038_bib18","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.01520-08","article-title":"Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs","volume":"53","author":"Goutelle","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jtbi.2016.03.038_bib19","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiu610","article-title":"Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia","volume":"211","author":"Gumbo","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jtbi.2016.03.038_bib20","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jtbi.2016.03.038_bib21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1086\/510247","article-title":"Isoniazid\u05f3s bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth","volume":"195","author":"Gumbo","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jtbi.2016.03.038_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tube.2005.08.008","article-title":"Animal models of tuberculosis","volume":"85","author":"Gupta","year":"2005","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jtbi.2016.03.038_bib23","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/ajrccm.156.3.9612016","article-title":"Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group","volume":"156","author":"Hafner","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jtbi.2016.03.038_bib24","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jtbi.2016.03.038_bib25","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1128\/AAC.48.8.2951-2957.2004","article-title":"Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis","volume":"48","author":"Jayaram","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jtbi.2016.03.038_bib26","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","article-title":"Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days","volume":"167","author":"Jindani","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jtbi.2016.03.038_bib27","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"key":"10.1016\/j.jtbi.2016.03.038_bib28","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1128\/AAC.00462-15","article-title":"Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs","volume":"59","author":"Lalande","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jtbi.2016.03.038_bib29","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/jhep.2001.28509","article-title":"Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed","volume":"34","author":"Lewin","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jtbi.2016.03.038_bib30","first-page":"187","article-title":"Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance","volume":"2","author":"Lipsitch","year":"1998","journal-title":"Int. J. Tuberc. Lung"},{"key":"10.1016\/j.jtbi.2016.03.038_bib31","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10928-015-9419-z","article-title":"Computational pharmacokinetics\/pharmacodynamics of rifampin in a mouse tuberculosis infection model","volume":"42","author":"Lyons","year":"2015","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"162","key":"10.1016\/j.jtbi.2016.03.038_bib32","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.4049\/jimmunol.162.11.6740","article-title":"Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates","volume":"1950","author":"Manca","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtbi.2016.03.038_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtbi.2003.11.023","article-title":"The human immune response to Mycobacterium tuberculosis in lung and lymph node","volume":"227","author":"Marino","year":"2004","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.jtbi.2016.03.038_bib34","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison","year":"2000","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"key":"10.1016\/j.jtbi.2016.03.038_bib35","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1086\/518046","article-title":"Isoniazid activity is terminated by bacterial persistence","volume":"195","author":"Mitchison","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jtbi.2016.03.038_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jtbi.2016.03.038_bib37","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.177.6.1723","article-title":"Mycobacterial virulence. Virulent strains of Mycobacteria tuberculosis have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity","volume":"177","author":"North","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtbi.2016.03.038_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10096-004-1109-5","article-title":"Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections","volume":"23","author":"Nuermberger","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"10.1016\/j.jtbi.2016.03.038_bib39","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1093\/cid\/civ615","article-title":"T-Cell therapy: options for infectious diseases","volume":"61","author":"Parida","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.jtbi.2016.03.038_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00749-10","article-title":"An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future","volume":"55","author":"Pasipanodya","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jtbi.2016.03.038_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/174.1.105","article-title":"Comparable growth of virulent and avirulent Mycobacterium tuberculosis in human macrophages in vitro","volume":"174","author":"Paul","year":"1996","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jtbi.2016.03.038_bib42","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1128\/AAC.41.12.2670","article-title":"Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide","volume":"41","author":"Peloquin","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jtbi.2016.03.038_bib43","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtbi.2014.11.021","article-title":"A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment","volume":"367","author":"Pienaar","year":"2015","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.jtbi.2016.03.038_bib44","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/AAC.48.3.780-782.2004","article-title":"Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study","volume":"48","author":"Pletz","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jtbi.2016.03.038_bib45","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tips.2015.05.005","article-title":"Exploring the potential of adjunct therapy in tuberculosis","volume":"36","author":"Rayasam","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jtbi.2016.03.038_bib46","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1371\/journal.pmed.0030273","article-title":"Prospects for advancing tuberculosis control efforts through novel therapies","volume":"3","author":"Salomon","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.jtbi.2016.03.038_bib47","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1128\/IAI.66.3.1190-1199.1998","article-title":"Expression of virulence of Mycobacterium tuberculosis within human monocytes: virulence correlates with intracellular growth and induction of tumor necrosis factor alpha but not with evasion of lymphocyte-dependent monocyte effector functions","volume":"66","author":"Silver","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jtbi.2016.03.038_bib48","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jac\/32.6.867","article-title":"The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment","volume":"32","author":"Sirgel","year":"1993","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jtbi.2016.03.038_bib49","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1164\/ajrccm.156.3.9611066","article-title":"The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis","volume":"156","author":"Sirgel","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jtbi.2016.03.038_bib50","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/45.6.859","article-title":"A multicentre study of the early bactericidal activity of anti-tuberculosis drugs","volume":"45","author":"Sirgel","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jtbi.2016.03.038_bib51","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.510290626","article-title":"Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy","volume":"29","author":"Tsiang","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jtbi.2016.03.038_bib52","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1086\/518044","article-title":"Persistence, not resistance, is the cause of loss of isoniazid effect","volume":"195","author":"Wallis","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"166","key":"10.1016\/j.jtbi.2016.03.038_bib53","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.4049\/jimmunol.166.3.1951","article-title":"A model to predict cell-mediated immune regulatory mechanisms during human infection with Mycobacterium tuberculosis","volume":"1950","author":"Wigginton","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtbi.2016.03.038_bib54","unstructured":"World Health Organization, 2015. Global tuberculosis report 2015"},{"key":"10.1016\/j.jtbi.2016.03.038_bib55","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nrmicro1919","article-title":"Systems biology of persistent infection: tuberculosis as a case study","volume":"6","author":"Young","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jtbi.2016.03.038_bib56","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.envsoft.2008.12.002","article-title":"GUI\u2013HDMR \u2013 a software tool for global sensitivity analysis of complex models","volume":"24","author":"Ziehn","year":"2009","journal-title":"Environ. Model. Softw."},{"issue":"2","key":"10.1016\/j.jtbi.2016.03.038_bib57","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1093\/infdis\/jir881","article-title":"Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs","volume":"205","author":"Zumla","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jtbi.2016.03.038_bib58","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(13)70328-1","article-title":"New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects","volume":"14","author":"Zumla","year":"2014","journal-title":"Lancet Infect. Dis."}],"container-title":["Journal of Theoretical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519316300145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519316300145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T14:03:08Z","timestamp":1692280988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022519316300145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":58,"alternative-id":["S0022519316300145"],"URL":"https:\/\/doi.org\/10.1016\/j.jtbi.2016.03.038","relation":{},"ISSN":["0022-5193"],"issn-type":[{"value":"0022-5193","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mathematical modeling and systems pharmacology of tuberculosis: Isoniazid as a case study","name":"articletitle","label":"Article Title"},{"value":"Journal of Theoretical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtbi.2016.03.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}